Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis by Takai, Atsuko et al.
RESEARCH ARTICLE Open Access
Fructo-oligosaccharides ameliorate
steatohepatitis, visceral adiposity, and
associated chronic inflammation via
increased production of short-chain fatty
acids in a mouse model of non-alcoholic
steatohepatitis
Atsuko Takai1, Kentaro Kikuchi1*, Mayuko Ichimura2, Koichi Tsuneyama2, Yuki Moritoki3, Kotaro Matsumoto4,
Hiromichi Tsunashima4, Takeshi Onda4,5, Noriyuki Kuniyoshi4,6, Tomoyuki Nariyama1, Sho Ohyatsu1, Juri Kubota1,
Kozue Nagumo1, Shinpei Sato1, Masumi Hara1 and Hiroshi Miyakawa1
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome. Within
the spectrum of NAFLD, non-alcoholic steatohepatitis (NASH) in combination with hepatic inflammation and
fibrosis can lead to liver cirrhosis and hepatocellular carcinoma. Dysbiosis was reported to contribute to NASH
pathogenesis. This study aimed to determine the effects of fructo-oligosaccharides (FOS) on steatohepatitis and
visceral adiposity in an obese mouse model of NASH.
Methods: Twelve newborn C57BL/6 J male mice were subcutaneously injected with monosodium glutamate (MSG)
to induce obesity on a conventional diet. Six mice were also administered 5% FOS via drinking water from 10
weeks of age. At 18 weeks, histological characteristics of the liver and epididymal fat were compared between the
groups. Hepatic mRNA expression of lipid metabolism enzymes and SCFA in feces and sera were measured.
Results: Hepatic steatosis, inflammatory cell infiltration, and hepatocyte ballooning in the liver and increased
hepatic mRNA expression of fatty acid synthase and glycerol-3-phosphate acyltransferase were observed in the
MSG-treated mice. FOS treatment improved the liver pathology and blunted the increases in the mRNA expression
levels of lipid metabolism enzymes. In addition, FOS inhibited adipocyte enlargement and formation of crown-like
structures and reduced the M1 macrophage frequency in the epididymal fat of the MSG mice (39.4% ± 3.0% vs.
22.8% ± 0.7%; P = 0.001). FOS increased not only the fecal concentrations of n-butyric acid (0.04 ± 0.01 vs. 0.38 ± 0.14
mg/g, P = 0.02), propionic acid (0.09 ± 0.03 vs. 0.42 ± 0.16 mg/g, P = 0.02), and acetic acid (0.65 ± 0.16 vs. 1.48 ± 0.29
mg/g, P = 0.03) but also the serum concentration of propionic acid (3.9 ± 0.5 vs. 8.2 ± 0.5 μmol/L, P = 0.001).
Conclusions: FOS ameliorates steatohepatitis, visceral adiposity, and chronic inflammation by increasing SCFA
production.
Keywords: Fructo-oligosaccharides, Monosodium glutamate, Non-alcoholic fatty liver disease, Non-alcoholic
steatohepatitis, Short-chain fatty acids
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Background
Non-alcoholic fatty liver disease (NAFLD) is often ac-
companied by obesity, type 2 diabetes mellitus, and dys-
lipidemia and is therefore considered a hepatic
manifestation of metabolic syndrome [1]. Among the
various forms of NAFLD, non-alcoholic steatohepatitis
(NASH) involves hepatic inflammation and fibrosis,
which can lead to cirrhosis, and the reported five-year
cumulative incidence of liver cancer among patients with
cirrhosis is 20% in Japan [2].
Recent analyses revealed that bacterial flora and diet-
ary microbial metabolites, such as SCFA, contributed to
homeostasis as well as various diseases in humans [3].
An imbalance in the microbiota, the bacterial flora of
the gastrointestinal tract, termed dysbiosis, was recently
reported to be involved in inflammatory bowel disease,
type 2 diabetes mellitus, and autism [4, 5].
In NASH, dysbiosis can stem from an unbalanced diet
or obesity, and a reduction in the production of SCFA
can lead to a dysfunctional intestinal mucosal barrier
and immunological disorders [6]. Studies showed that a
large number of pathogen-associated molecular patterns
could access the liver through disrupted intestinal muco-
sal epithelia, causing Kupffer cell hypersensitivity, and
could lead to steatohepatitis [7–9].
We recently reported that fructo-oligosaccharides
(FOS), which are prebiotics, ameliorated dysbiosis and
improved intestinal barrier function, thereby suppressing
Kupffer cell activation and improving steatohepatitis in
mice fed a methionine/choline-deficient diet (MCD)
[10]. FOS, which are found in foods that are not digested
or absorbed in the upper gastrointestinal tract, are fer-
mented selectively by beneficial intestinal bacteria.
Therefore, FOS induce favorable changes in the intes-
tinal bacterial flora and have health-promoting effects in
the entire body [11, 12].
MCD-fed mice in the NASH model do not exhibit
obesity or insulin resistance; thus, the mechanism
underlying the effect of FOS on lipid metabolism in
the liver or visceral fat levels cannot be examined,
whereas the monosodium glutamate (MSG)-treated
mouse is an appropriate animal model of NASH.
Neonatal administration of MSG in rodents was pre-
viously demonstrated to affect the arcuate nucleus
and the ventromedial nucleus of hypothalamus and to
impair leptin signaling, resulting in obesity in rodents
that were fed a conventional diet [13, 14]. Nakanishi
et al. first reported that an injection of MSG in Insti-
tute of Cancer Research mice leads to the develop-
ment of a significant human NASH-like liver
histology [15]. In recent years, MSG-treated mice
have been widely used in human NASH research
[16–19]. Therefore, we investigated the mechanism by
which FOS ameliorate steatohepatitis and tested our
hypothesis that FOS alleviate visceral adiposity using
an MSG-treated obese mouse model of NASH.
Methods
Generation of the NASH mouse model and FOS
administration
The MSG-treated mouse model of NASH was described
previously [20, 21]. Briefly, MSG (Wako Pure Chemical
Industries, Osaka, Japan) in normal saline at a dose of 4
mg/g body weight was subcutaneously injected into the
backs of 12 male C57BL/6 J mice (Sankyo Labo Service,
Tokyo, Japan) at 1 week of age. All mice were fed a con-
ventional diet and purified water and housed under con-
ventional conditions. Six of the MSG-treated mice were
administered 5% FOS (Meioligo W; Meiji Corporation,
Tokyo, Japan) in their drinking water in addition to the
conventional diet, starting at 10 weeks of age. These
mice in the MSG + FOS group were housed under the
same conditions as those in the MSG group. The control
group comprised six male mice aged 1 week that were
subcutaneously injected with saline at the same volume
as MSG and fed the same diet and purified water and
housed under the same conditions as the mice in the
MSG group. The body weight of all mice was measured
periodically up to 18 weeks of age.
This study was approved by the Teikyo University
School of Medicine Animal Ethics Committee (approval
number: 14–030) and was conducted in accordance with
the relevant institutional guidelines.
Serological and histological analyses
At 18 weeks of age, the mice were anesthetized with in-
traperitoneal administration of 75 mg/kg ketamine
hydrochloride and 1mg/kg medetomidine chloride, and
the levels of blood glucose, insulin, total cholesterol, adi-
ponectin and alanine aminotransferase (ALT) in serum
samples of venous blood were measured. The serum
concentrations of n-butyric acid, propionic acid, and
acetic acid were measured using the GCMS-QP2010
Ultra/SE gas chromatography system (Shimadzu Corpor-
ation, Kyoto, Japan) [22]. The mice were sacrificed by
cervical dislocation, and the livers were weighed and
perfused with PBS containing 0.5% bovine serum albu-
min and 0.04% EDTA (PBS buffer) that was adminis-
tered from the inferior vena cava before their removal.
Half of each liver was fixed in 4% paraformaldehyde,
stained with hematoxylin and eosin, and histopathologic-
ally evaluated according to the NAFLD activity score
(NAS) [23]. The remainder of each liver was snap-frozen
in liquid nitrogen and stored at − 80 °C until analysis by
real-time PCR.
The epididymal fat of the mice was excised from the peri-
toneal cavity and weighed. Half of the epididymal fat was
fixed in 4% paraformaldehyde, stained with hematoxylin
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and eosin, and evaluated histopathologically. The remaining
fat was sliced thinly before dissociation by passing through
a cell strainer with a mesh size of 40 μm (BD Falcon, Dur-
ham, NC, USA). The dissociated cells were suspended in
PBS buffer and centrifuged for 5min at 1000 rpm. The
supernatant was discarded, and the pellet was resuspended
in PBS buffer, layered on Lymphoprep (Axis-Shield Proc.
AS, Oslo, Norway) at a relative density of 1.077, and centri-
fuged for 15min at 1400 rpm to isolate the stromal vascular
fraction (SVF), which was collected using a pipette and
washed in PBS buffer. The number of viable cells in the
SVF was counted using trypan blue staining.
Analysis of the bacterial flora and SCFA in feces
Feces were collected from the cecum to analyze the bac-
terial flora and measure SCFA concentrations. The par-
tial amino acid sequence of bacterial 16 s rDNA was
analyzed using the terminal restriction fragment length
polymorphism (T-RFLP) technique based on Nagashi-
ma’s method [24]. Briefly, 20 mg feces was dissolved in
0.2 ml distilled water and rinsed via centrifugation. The
resultant pellet was dissolved in 250 μl Tris-EDTA buffer
containing 100 mM Tris-HCl and 40 mM of EDTA.
After centrifugation with 0.6 g DNA extraction beads,
the supernatant was collected and mixed with 150 μl
benzyl chloride and 50 μl 10% sodium lauryl sulfate for
30 min at 50 °C. After centrifugation with 150 μl 3 M so-
dium acetate, the supernatant was collected and mixed
with isopropyl alcohol for DNA extraction. Next, 0.5 U
of HotStarTaq DNA polymerase (Qiagen, Tokyo, Japan)
was added to 10 ng DNA, and bacterial 16 s rDNA was
amplified via PCR using the 5′ terminal fluorolabeled
516f and 1510r primer sets [24]. After the digestion of
DNA with the restriction enzyme Bsl I, the resultant
fragments were analyzed using an ABI PRISM 3130xl
DNA sequencer (Applied Biosystems, Carlsbad, CA,
USA) and the GeneMapper software (Applied Biosys-
tems). The length of each fragment was determined
based on operational taxonomic units, and peak area ra-
tios were presented as percentages.
In addition, 1 g feces was pulverized under sterile con-
ditions. The fecal SCFA concentrations were analyzed
using the Prominence HPLC system (Shimadzu Corpor-
ation, Kyoto, Japan).
Gene expression analysis
Total RNA was extracted from the liver using RNAiso
Plus (Takara Bio, Shiga, Japan), and cDNA was synthe-
sized using the ReverTra Ace qPCR RT master mix
(Toyobo, Osaka, Japan). Real-time PCR was performed
with the Thunderbird SYBR qPCR mix (Toyobo) using
the LightCycler® Nano system (F. Hoffmann-La Roche,
Basel, Switzerland), as described previously [25]. Specific
primers were designed using the Primer-BLAST primer
designing tool (National Center for Biotechnology Infor-
mation, Bethesda, MD, USA) and were synthesized by
FASMAC (Kanagawa, Japan). The relative mRNA ex-
pression levels were normalized to the expression level
of β-actin.
Flow cytometric analysis
Flow cytometry was used to analyze M1 and M2 adipose
tissue macrophages (ATM). All antibodies and the cell-
staining buffer were obtained from BioLegend (San
Diego, CA, USA). To prevent non-specific staining, a
total of 1 × 106 SVF cells were incubated with 1 μl puri-
fied anti-mouse CD16/32 antibody (clone 93) in 24 μl
cell-staining buffer containing sodium azide for 10 min
at 4 °C. Fluorescein isothiocyanate-conjugated anti-
mouse F4/80 antibody (clone BM8), phycoerythrin (PE)-
conjugated anti-mouse CD11c antibody (clone N418),
allophycocyanin (APC)-conjugated anti-mouse CD11b
antibody (clone M1/70), APC/Cy7-conjugated anti-
mouse CD86 antibody (clone GL-1), PE-conjugated
American Hamster IgG isotype control antibody (clone
HTK888) and APC/Cy7-conjugated Rat IgG2a-kappa
isotype control antibody (clone KLH) in 25 μl cell-
staining buffer were added to the cells and incubated in
the dark for 10 min at 4 °C After washes, the labeled
cells were resuspended in 200 μl PBS buffer, transferred
to the wells of 96-well round-bottomed plates, and ana-
lyzed on a BD FACSArray flow cytometer (BD Immuno-
cytometry Systems, San Jose, CA, USA).
Statistical analysis
Mouse body weight, epididymal fat weight, total serum
cholesterol level, serum ALT level, serum and fecal
levels of SCFA, NAS, mRNA expression levels, and fre-
quencies of M1 and M2 ATM were expressed as means
± standard error of the mean. The mean fluorescence in-
tensity (MFI) ratios of CD86 was calculated as the sam-
ple MFI divided by the isotype control MFI. All
statistical analyses were performed using one-way
ANOVA with Tukey’s post hoc test using GraphPad
Prism version 6.0 for Macintosh (GraphPad Software,
San Diego, CA, USA), and differences were considered
significant at a P value of < 0.05.
Results
Physical and serological characteristics
At 10 weeks of age, the mice in both the MSG and
MSG + FOS groups were heavier than the control mice
(MSG, 26.5 ± 0.6 g; MSG + FOS, 26.3 ± 0.5 g; control,
23.1 ± 0.5 g; p = 0.001 for both; Fig. 1a). The mean body
weights did not differ between the MSG and the MSG +
FOS mice at 18 weeks of age (34.9 ± 2.4 and 35.6 ± 2.0 g,
respectively; p = 0.9). Conversely, at 18 weeks of age, the
MSG + FOS mice exhibited a lower mean epididymal fat
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weight than the MSG mice (MSG, 2.7 ± 0.2 g; MSG +
FOS, 2.3 ± 0.1 g; p = 0.04; Fig. 1b). Moreover, the MSG +
FOS mice exhibited a lower mean liver weight than the
MSG mice (MSG, 2.3 ± 0.1 g; MSG + FOS, 1.9 ± 0.3 g;
p = 0.04; Fig. 1c).
The mean blood glucose and insulin levels of the MSG
mice (265.4 ± 14.1 mg/dL, 10.4 ± 1.7 ng/dL) were higher
than that of the control mice (160.0 ± 14.0 mg/dL, 4.4 ±
1.3 ng/dL; p = 0.001 for both). Compare to the MSG
mice, MSG + FOS mice had lower levels of blood glucose
and insulin (161.2 ± 15.8 mg/dL, 4.0 ± 1.2 ng/dL; p =
0.001 for both; Fig. 1d, e). The mean total cholesterol
level of the MSG mice (148.6 ± 14.5 mg/dL) was higher
than that of the control mice (85.6 ± 2.2 mg/dL; p =
0.001) and MSG + FOS mice (115.6 ± 8.7 mg/dL; p =
0.003; Fig. 1f). The mean adiponectin level of the MSG
mice (37.7 ± 4.4 μg/mL) was lower than that of control
mice (69.8 ± 13.8 μg/mL; p = 0.003; Fig. 1g). In MSG +
FOS mice, serum adiponectin level (58.7 ± 9.4 μg/mL)
was increased compare to MSG mice (p = 0.04).
Histological characteristics of the liver
Hepatic steatosis, inflammatory cell infiltration, and bal-
looning hepatocytes were observed in the livers of the
MSG mice (Fig. 2a), whereas these changes were less
marked in the livers of the MSG + FOS mice. According
to the NAS, steatosis (MSG, 1.7 ± 0.4; MSG + FOS, 0.3 ±
0.4; p = 0.001), lobular inflammation (MSG, 1.0 ± 0.3;
MSG + FOS, 0.2 ± 0.1; p = 0.001) and ballooning degen-
eration (MSG, 1.7 ± 0.4; MSG + FOS, 0.3 ± 0.4; p = 0.001)
were less severe in the MSG + FOS mice compared with
the MSG mice (Fig. 2b).
The mean serum ALT level of the MSG mice was
higher than that of the control mice (MSG, 108.3 ± 29.0
U/L; control, 39.2 ± 0.9 U/L; p = 0.001; Fig. 2c). Con-
versely, the mean serum ALT level of the MSG + FOS
mice was lower than that of the MSG mice (MSG + FOS,
73.5 ± 7.0 U/L; p = 0.001).
The hepatic mRNA expression levels of lipid biosynthesis
enzymes
In the MSG mice, the hepatic mRNA levels of enzymes
linked to lipid biosynthesis were elevated. The mean
relative mRNA expression levels of fatty acid synthase
(control, 1.0 ± 0.17; MSG, 1.96 ± 0.51; p = 0.02) and
glycerol-3-phosphate acyltransferase (control, 1.0 ± 0.13;
MSG, 2.0 ± 0.33; p = 0.01) were significantly higher in
the MSG mice than in the control mice (Fig. 3). Add-
itionally, the hepatic mRNA expression levels of these
enzymes were lower in the MSG + FOS mice (fatty acid
synthase, 0.57 ± 0.06; p = 0.02; glycerol-3-phosphate acyl-
transferase, 1.01 ± 0.07; p = 0.01) than the MSG mice.
Fig. 1 Physical and serological findings of the control, MSG, and MSG + FOS mice. a Changes in mean body weight, and at 18 weeks of (b)
epididymal fat weight, c liver weight, d serum blood glucose levels, e serum insulin levels, f serum total cholesterol levels, and (g) serum
adiponectin levels. *p < 0.05, **p < 0.01. FOS, fructo-oligosaccharides; MSG, monosodium glutamate
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There were no differences among groups in molecules
involved in lipid uptake (fatty acid transport protein 5),
lipolysis (carnitine palmitoyltransferase), or lipid transfer
(microsomal triglyceride transfer protein).
Histopathological characteristics of the epididymal fat
and the frequency of M1-like ATM
Enlarged adipocytes and crown-like structures were ob-
served in the epididymal fat of the MSG mice (Fig. 4a),
whereas FOS treatment led to smaller adipocytes and
prevented the formation of crown-like structures in the
MSG + FOS mice. To assess the numbers of macro-
phages in the epididymal tissue, F4/80+ and CD11bhigh
cells were collected from the SVF, and M1-like ATM
were identified as CD11c+ cells [26]. The proportion of
M1-like ATM was 39.4% ± 3.0% of the SVF cells in the
MSG mice, which was significantly higher than that in
the control mice (9.1% ± 0.4%; p = 0.001; Fig. 4b). In the
MSG + FOS mice, the proportion of M1-like ATM
(22.8% ± 0.7%; p = 0.001) was significantly lower than
that in the MSG mice. The MFI ratio of CD86 in M1-
like ATM was 4.6 ± 1.8 in control mice, 12.4 ± 1.6 in
MSG mice (vs. control mice; p = 0.001) and 5.5 ± 1.2 in
MSG + FOS mice (vs MSG mice; p = 0.01; Fig. 4c).
The bacterial composition of feces
The analysis of the bacterial composition of feces re-
vealed that the frequency of Clostridium cluster XI,
which was 3.6% in the control mice, was reduced to
1.3% in the MSG mice (p = 0.04), whereas the frequency
of the bacteria classified as “others” was reduced from
17.5% in the control mice to 8.4% the MSG mice (p =
0.01). Conversely, the frequency of the genus Prevotella,
which was 1.3% in the control mice, was increased to
8.7% in the MSG mice (p = 0.01) (Additional file 1: Fig-
ure S1). The feces of the MSG + FOS mice displayed a
recovery of bacterial balance. Specifically, the frequencies
of Clostridium cluster XI, “others”, and the genus Prevo-
tella were 7.8, 12.1, and 1.8%, (p < 0.05 for both)
respectively.
The levels of SCFA in feces and serum
The analysis of the SCFA levels in feces revealed that
the mean fecal concentrations of n-butyric acid, propio-
nic acid, and acetic acid were significantly lower in the
MSG mice than the control mice (0.04 ± 0.01, 0.09 ±
0.03, and 0.65 ± 0.16 mg/g vs. 0.48 ± 0.11, 0.56 ± 0.09,
and 2.46 ± 0.43 mg/g; p = 0.02, 0.02, and 0.007, respect-
ively; Fig. 5). Conversely, the mean fecal concentrations
of n-butyric acid, propionic acid, and acetic acid in the
Fig. 2 Liver findings and serum ALT levels in the control, MSG, and MSG + FOS mice at 18 weeks. a Histological findings (hematoxylin/eosin
staining, 100× magnification, scale bar = 100 μm), b Mean NAFLD activity score, c Mean serum ALT levels. **p < 0.01. ALT, alanine
aminotransferase; FOS, fructo-oligosaccharides; MSG, monosodium glutamate; NAFLD, non-alcoholic fatty liver disease
Takai et al. BMC Gastroenterology           (2020) 20:46 Page 5 of 10
MSG + FOS mice (0.38 ± 0.14, 0.42 ± 0.16, and 1.48 ±
0.29 mg/g, respectively) were significantly higher than
those in the MSG mice (p = 0.02, 0.02, and 0.03,
respectively).
The mean serum concentrates of n-butyric acid and
acetic acid did not differ among the three groups (p >
0.05 in all cases). However, the mean serum concentra-
tion of propionic acid was significantly lower in the
MSG mice (3.9 ± 0.5 μmol/L) than in the control mice
(5.9 ± 0.4 μmol/L; p = 0.03). In the MSG + FOS mice, the
mean serum concentration of propionic acid (8.2 ±
0.5 μmol/L) was significantly higher than that in the
MSG mice (p = 0.001).
Discussion
The current study utilizing an obese mouse model of
NASH revealed that FOS ameliorated dysbiosis and in-
creased SCFA production by the intestinal bacterial
flora. Hepatic steatosis and inflammatory cell infiltration
were also ameliorated by the administration of FOS. In
addition, visceral adiposity and associated chronic in-
flammation was significantly reduced by FOS.
In a previous study to elucidate the mechanism under-
lying the FOS-mediated amelioration of steatohepatitis,
we reported that the increased SCFA production by the
bacteria provided nutrients to intestinal epithelial cells,
improved intestinal barrier function, increased immuno-
globulin A production, and suppressed Kupffer cell acti-
vation in MCD-fed mice [10]. In the current study, we
focused on the effect of SCFA on lipid biosynthesis in
the liver and visceral adiposity and associated chronic in-
flammation using an obese mouse model of NASH.
There are three additional potential explanations for
the observed beneficial effects of SCFA in the present
study. First, SCFA promotes glucagon-like peptide-1
(GLP-1) secretion from the L cells of the intestinal tract
[27], given that several recent clinical studies demon-
strated that treatment with GLP-1, which regulates hep-
atic lipid accumulation [28]. Recent studies have shown
the efficacy of GLP-1 in treating NAFLD [29, 30]. Sec-
ond, adipocytes express SCFA receptor G-protein-
coupled receptor 43 (GPR43). Kimura et al. reported
that GPR43 can act to suppress insulin signaling in adi-
pocytes and inhibit fat accumulation in adipose tissue as
Fig. 3 Hepatic lipid metabolism-related genes in the control, MSG, and MSG + FOS mice at 18 weeks. mRNA levels were determined by real-time
PCR and are expressed relative to the levels in the control mice after normalization to β-actin mRNA expression. *p < 0.05, **p < 0.01. FOS, fructo-
oligosaccharides; MSG, monosodium glutamate
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well as promote the metabolism of unincorporated lipids
and glucose in the liver [31]. Third, SCFA can act as a
ligand for peroxisome proliferator-activated receptor-γ
(PPARγ), resulting in improved insulin sensitivity. den
Besten et al. reported that SCFA-induced reduction of
hepatic steatosis was absent in mice lacking hepatic
PPARγ [32]. Mattace et al. reported that butyrate sup-
plementation decreased pro-inflammatory markers
interleukin-6 and nuclear factor-kappa B, thus increasing
the threshold for inflammatory responses in the liver of
high-fat diet-fed rats [33].
In the current study, we found that FOS signifi-
cantly increased the serum concentration of propionic
acid and reduced the mRNA expression levels of fatty
acid synthase and glycerol-3-phosphate acyltransferase.
Propionic acid was reported to reduce the hepatic
mRNA and protein expression of lipid biosynthetic
enzymes [34], increase glucose transporter type 4
(GLUT4) and improve insulin sensitivity [35], and in-
hibit lipopolysaccharide-stimulated tumor necrosis
factor-α release by neutrophils [36]. Our future stud-
ies should elucidate the roles of SCFA and propionic
acid in detail.
The effect of FOS on liver fibrosis was not evaluated,
which was a limitation of the current study. MSG mice
do not exhibit severe hepatic fibrosis, albeit displaying
severe steatosis and inflammation compared to other
NASH model animals [37]. The present study results
suggested that the administration of FOS is an effective
treatment for not only early-stage NASH but also vis-
ceral adiposity and associated chronic inflammation.
Similar to MSG mice, ob/ob mice affect leptin signaling
resulting obesity, hyperglycemia, and hepatic steatosis.
However, MSG mice show more hepatic inflammation
than ob/ob mouse [37].
Various methods to date were proposed to abrogate
dysbiosis. In a study examining the outcomes follow-
ing the administration of useful bacteria as probiotics
in a NASH animal model, Velayudham et al. con-
firmed the attenuation of hepatic fibrosis and the
downregulation of the hepatic mRNA expression
levels of toll-like receptor 4 and CD14 in MCD mice
that were fed VSL#3, is a probiotic formula including
eight useful bacterial species, for 10 weeks. However,
the authors could not confirm whether the treatment
was associated with a significant alleviation of steato-
sis or inflammation [38]. Conversely, Endo et al. dem-
onstrated that the tight junctions between the
intestinal epithelial cells were reinforced and that
steatosis and fibrosis were improved in the livers of
Fig. 4 Visceral fat findings in the control, MSG, and MSG + FOS mice at 18 weeks. a Histological findings (hematoxylin/eosin staining, 100×
magnification, scale bar = 100 μm), b Flow cytometric analysis of ATM. ATM were defined as F4/80+ CD11bhigh cells. Among the ATM, M1-like
macrophages were defined as CD11c+ cells. c MFI ratio of CD86 in F4/80+ CD11bhigh CD11c+ cells. ATM, adipose tissue macrophages; FOS, fructo-
oligosaccharides; MSG, monosodium glutamate; MFI, mean fluorescence intensity
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choline-deficient/L-amino acid-defined diet-fed rats
that were administered butyric acid-producing bac-
teria for 8–50 weeks [39]. However, abrogating dys-
biosis by the administration of a single bacterial
species may not be feasible. Recent clinical trials re-
ported that synbiotic yogurt consumption improved
hepatic steatosis in patients with NAFLD [40]. There-
fore, investigating the effect of FOS on NASH re-
mains an important approach.
Conclusions
In conclusion, the current study provides a potential
dietary strategy for the prevention and treatment of
NASH, visceral adiposity, and associated chronic inflam-
mation. At present, there are no approved therapies for
NASH. Prebiotics such as FOS are found in onion, gar-
lic, soybeans, and burdock and produced industrially as
syrups. Thus, FOS are more appropriate for habitual
consumption compared with probiotics. The effects of
FOS on lifestyle-related diseases have been increasingly
reported [41]. Future studies should elucidate the contri-
bution of FOS to human health.
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